The Medicines Company (MDCO)
-NasdaqGS 32.06 
1.65(4.89%) 12:58PM EDT - Nasdaq Real Time Price
| Prev Close: | 33.71 |
|---|
| Open: | 33.40 |
|---|
| Bid: | 32.14 x 400 |
|---|
| Ask: | 32.17 x 100 |
|---|
| 1y Target Est: | 37.14 |
|---|
| Beta: | 0.93 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 30.85 - 34.33 |
|---|
| 52wk Range: | 20.04 - 37.40 |
|---|
| Volume: | 2,219,401 |
|---|
| Avg Vol (3m): | 837,838 |
|---|
| Market Cap: | 1.73B |
|---|
| P/E (ttm): | 54.71 |
|---|
| EPS (ttm): | 0.59 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Stocks Stage Broad Advance; Bristol-Myers Leads Medicalsat Investor's Business Daily(Wed 12:09PM EDT)
- Stocks Get A Boost From Dovish Fed Remarksat Investor's Business Daily(Tue, May 21)
- MEDICINES CO /DE Files SEC form 8-K, Other EventsEDGAR Online(Mon, May 20)
- IBD 50: Top 5 Medical Stocks Include Celgene, Actavisat Investor's Business Daily(Sat, May 18)
- MEDICINES CO /DE FinancialsEDGAR Online Financials(Fri, May 17)
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- Why The Medicines Company May Be About to Take Offat Motley Fool(Thu, May 16)
- The Medicines Company CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- Pediatric Approval for MDCO/BMY's RecothromZacks(Wed, May 15)
- Actavis Joins Other Drugmakers On Elite IBD 50at Investor's Business Daily(Sat, May 11)
- MEDICINES CO /DE Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Biotech Stocks Dominate Your Weekly Review Listat Investor's Business Daily(Thu, May 9)
- Stocks Ease After Recent Gains;Nationstar, Ocwen Buck Trendat Investor's Business Daily(Thu, May 9)
- Stocks Mixed In Afternoon; Rackspace, SS&C Plungeat Investor's Business Daily(Thu, May 9)
- RECOTHROM Becomes the First and Only Topical Thrombin Indicated for Use in Children Greater Than or Equal to One Month of AgeMarketwired(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 20.89 |
|---|
| P/S (ttm): | 3.10 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.32 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 0.91 |
|---|
Business Summary
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients ...
View More